ClinicalTrials.gg
RecruitingNCT05782686Updated Sep 17, 2026

Impact of Systematic Shaving on Margins

An interventional study of Margin shaving in Margin, Tumor-Free, Breast Cancer and Surgery, sponsored by Hospital Universitari de Bellvitge. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Hospital Universitari de Bellvitge · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Oct 2020, registered Mar 2023).
  • Started Oct 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The objective of this clinical trial is to demonstrate the reduction of positive margins in the definitive pathology of patients undergoing breast-conserving surgery with the systematic shaving technique compared to conventional surgery, and the reduction of second interventions for margin enlargement.

Read the detailed description

Patients with breast cancer who undergo breast-conserving surgery are randomized in the operating room after lumpectomy into 2 groups of 117 patients each: shaving/no-shaving (standard surgery).

02

Conditions studied

  • Margin, Tumor-Free
  • Breast Cancer
  • Surgery
03

In context

Margins of Excision

94 studies on the registry are indexed under Margins of Excision; 38 are open to participants now.

This study's planned enrollment of 234 is above the median of 87 across 65 interventional studies indexed under Margins of Excision.

Browse Margins of Excision studies →

Lead sponsor

Hospital Universitari de Bellvitge is the lead sponsor of 120 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Breast-conserving surgery.
  2. Imaging diagnosis as the only breast tumor focus according to mammography, breast ultrasound and/or nuclear magnetic resonance;
  3. Pathological diagnosis of carcinoma in situ or infiltrating
  4. Oncoplastic without associated flaps;

Exclusion criteria

Exclusion Criteria:

  1. Male patients;
  2. Patients with a history of ipsilateral breast cancer.
  3. Oncoplastic that includes flaps
  4. Multifocality or multicentricity;
  5. Pregnant or lactating patient;
  6. Stage IV patients;
  7. Patients eligible for mastectomy;
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
234 participants (estimated)

Study arms

  • Experimental
    Shaving

    Subsequent to lumpectomy, a circumferential enlargement of all lumpectomy margins, including lateral, medial, superior, inferior, anterior, and posterior, approximately 5-10mm thick, will be resected.

    Procedure: Margin shaving

  • Active comparator
    No Shaving

    Standard lumpectomy

    Procedure: Margin shaving

Interventions

  • ProcedureMargin shaving

    In both cohorts, an intraoperative study of the margins will be carried out, and enlargement of those margins that are affected will be carried out as indicated by the pathologist. Subsequently, shaving is performed in case of being randomized to the study group or surgery is completed in the control group.

06

What researchers measure

Primary outcomes

  1. Margin involvement

    To compare the number of cases with affected margins in the definitive pathological anatomy, of the cases with intraoperative systematic shaving versus the group of no shaving

    Time frame: 3 weeks after each surgery

  2. Re-interventions

    Demonstrate the reduction of second surgeries to widen affected margins in breast conserving surgery with the shaving technique

    Time frame: 3 weeks after each surgery

Secondary outcomes

  1. Shaving versus intraoperative pathological study

    Assess the possibility of replacing the intraoperative study of the margins with systematic shaving

    Time frame: 3 weeks after each surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Jun 2027, 80 months after the start.

Of 28 interventional studies with no phase under Margins of Excision, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 63. This study's planned 80 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2023
First posted
Mar 23, 2023
StartActual
Oct 7, 2020
Primary completionEst.
Jun 16, 2027
CompletionEst.
Oct 16, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05782686
Responsible party
Amparo Garcia-Tejedor (Clinical Professor, Hospital Universitari de Bellvitge) — Principal investigator
First posted
Mar 23, 2023
Start date
Oct 7, 2020
Primary completion
Jun 16, 2027 (estimated)
Completion
Oct 16, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

amparo garcia-tejedor, MDPhD
Contact
agarciat@bellvitgehospital.cat
932607695
Amparo Garcia Tejedor, MDPhD
principal investigator · Hospital de Bellvitge. Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion